Olsutamig
Olsutamig is a bivalent humanized IgG4κ monoclonal antibody inhibitor targeting FOLH1/PSMA and CD3E. Olsutamig simultaneously binds to PSMA on the tumor cell surface and CD3E on the T cell surface, markedly activating T cells and thereby specifically killing prostate cancer cells[1][2].
Product Specifications
CAS Number
3034664-43-9
Product Name Alternative
REGN-4336
UNSPSC
12352100
Target
CD3; PSMA
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
References & Citations
[1]Zekri L, et al. An IgG-based bispecific antibody for improved dual targeting in PSMA-positive cancer. EMBO Mol Med. 2021 Feb 5;13 (2) :e11902.|[2]Internacionales D C. International Nonproprietary Names for Pharmaceutical Substances (INN) [J]. WHO Drug Information, 2025, 39 (2) .
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
